Abstract 3937
Background
Surgical resection is the only curative treatment for pancreatic cancer but is very invasive. It usually causes severe stress in patients and may cause pain and deterioration of quality of life (QOL). Patient-reported QOL data are essential for describing patient symptomatology and evaluating care to adequately manage symptoms. Here we evaluated changes in health-related QOL (HRQOL) and symptoms in pancreatic cancer patients after surgical intervention.
Methods
The institutional review board of our university approved this study (2012-1-403); patients provided written informed consent. A QOL questionnaire survey was administered preoperatively and at postoperative months 3, 6, and 12. We statistically evaluated the correlations between the Short Form 36 Health Survey version 2 (SF-36v2 Standard, Japanese), which measures HRQOL, and specific symptoms of hepatobiliary and pancreatic cancer, using data collected from 100 postoperative pancreatic cancer patients (subtotal stomach-preserving pancreatoduodenectomy (PD), 54 patients; distal pancreatectomy, 36 patients; total pancreatectomy (TP), 10 patients). Responses were analyzed by two-way ANOVA and Spearman’s correlation coefficient analysis; p < 0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
QOL was lowest at 3 months postoperatively on many domains of the SF-36v2 and had gradually improved by 12 months postoperatively. At 3 months, physical functioning (PF) (p < 0.001) and role-physical (RP) (p < 0.01) were significantly reduced in PD and TP patients. Also, QOL deterioration on SF-36v2 domains was correlated with weight loss (PF, RP, vitality (VT), role-emotional (RE); p < 0.05), worse bowel control (PF, BP, VT, RE, mental health (MH); p < 0.01-0.05), indigestion (PF, RP, GH, VT, social functioning, RE, MH; p < 0.001-0.05), appetite loss (all domains; p < 0.001-0.01), fatigue (PF, RE, MH; p < 0.05), and inability to perform usual activities (all domains, p < 0.001).
Conclusions
QOL after pancreatectomy can be improved by nutrition management, treatment combinations for symptoms related to digestion and absorption, and treatment for subjective symptoms including fatigue.
Clinical trial identification
Editorial acknowledgement
Think Science KK.
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP16K07140.
Disclosure
F. Motoi: Speaker Bureau / Expert testimony: Taiho Pharma, Mylan Japan, Daichi-Sankyo. M. Unno: Research grant / Funding (self): Taiho Pharma, Chugai; Research grant / Funding (institution): Taiho Pharma, Pfizer, Takeda, Chugai, Yakult, Asahi-Kasei. All other authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract